Evidence map›Paper›PMID 36332974›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2022

Development and Validation of a Lifetime Risk Model for Kidney Failure and Treatment Benefit in Type 2 Diabetes: 10-Year and Lifetime Risk Prediction Models.

Helena Bleken Østergaard, Stephanie H Read, Naveed Sattar, Stefan Franzén, Nynke Halbesma, Jannick A N Dorresteijn, Jan Westerink, Frank L J Visseren, Sarah H Wild, Björn Eliasson and 1 more

Open access · greenAbstract read
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

  • Commented on by
    2023
5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Helena Bleken ØstergaardDepartment of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Stephanie H ReadScottish Diabetes Research Network Epidemiology Group, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.
Naveed SattarInstitute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
Stefan FranzénSwedish National Diabetes Register, Center of Registers in Region, Gothenburg, Sweden.
Nynke HalbesmaScottish Diabetes Research Network Epidemiology Group, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.
Jannick A N DorresteijnDepartment of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Jan WesterinkDepartment of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Frank L J VisserenDepartment of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Sarah H WildScottish Diabetes Research Network Epidemiology Group, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.
Björn EliassonSwedish National Diabetes Register, Center of Registers in Region, Gothenburg, Sweden.
Joep van der LeeuwDepartment of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.
University of Edinburgh · GBCentre of Registers Vastra Gotaland · SEUniversity of Glasgow · GBUniversity of Gothenburg · SEBritish Heart Foundation · GBSint Franciscus Gasthuis · NL

Funding

British Heart Foundation FS/16/36/32205
6 · The paper itself

Abstract

BACKGROUND AND

objectivesIndividuals with type 2 diabetes are at a higher risk of developing kidney failure. The objective of this study was to develop and validate a decision support tool for estimating 10-year and lifetime risks of kidney failure in individuals with type 2 diabetes as well as estimating individual treatment effects of preventive medication. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The prediction algorithm was developed in 707,077 individuals with prevalent and incident type 2 diabetes from the Swedish National Diabetes Register for 2002-2019. Two Cox proportional regression functions for kidney failure (first occurrence of kidney transplantation, long-term dialysis, or persistent eGFR <15 ml/min per 1.73 m

resultsDuring a median follow-up of 6.8 years (interquartile range, 3.2-10.6), 8004 (1%) individuals with type 2 diabetes in the Swedish National Diabetes Register cohort developed kidney failure, and 202,078 (29%) died. The model performed well, with

conclusionsThis study derived and externally validated a prediction tool for estimating 10-year and lifetime risks of kidney failure as well as life years free of kidney failure gained with preventive treatment in individuals with type 2 diabetes using easily available clinical predictors. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2022_11_04_CJN05020422.mp3.

Indexed as

Diabetes Mellitus, Type 2Kidney TransplantationRenal InsufficiencyHumansRenal DialysisRisk Factorsdiabetes mellitusend stage kidney diseaseepidemiology and outcomesrisk factors

Identifiers

PMID36332974
PMCPMC9718022
OpenAlexW4308209216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.